XXXX for the treatment of @entity99 .

@entity1 @entity11884 @entity409 @entity1761 @entity99 @entity298
BACKGROUND: Previous studies suggest that @entity1761 is efficacious in the treatment of @entity99 . OBJECTIVE: To evaluate the efficacy and safety of @entity1761 in addition to @entity11884 in improving hospitalization outcomes in @entity1 with @entity99 . METHODS: Hospital records of @entity1 evaluated for liver transplantation at a single center between January 2006 and May 2008 were reviewed. Hospitalizations for @entity99 and other conditions and the incidence of spontaneous @entity298 and adverse events were analyzed. RESULTS: Charts of 65 @entity1 who were treated with @entity1761 and @entity11884 were analyzed. @entity1 received @entity11884 (20-120 g/d; @entity11884 phase) before treatment with @entity1761 (400- 1200 mg/d; @entity1761 phase). During the @entity1761 phase, the risk, number, and duration of hospitalizations for @entity99 were reduced compared with the @entity11884 phase. Treatment, age, and Model for End-Stage @entity409 score were independent predictors of hospitalizations for @entity99 (P < .05). The @entity1761 phase had fewer hospitalizations than the @entity11884 phase (36 vs 47, respectively) and a smaller percentage of @entity1 with repeated hospitalizations than the @entity11884 phase (5% vs 14%, respectively; P = .006) for conditions other than @entity99 . A smaller percentage of @entity1 had evidence of spontaneous @entity298 during the @entity1761 phase than the @entity11884 phase (2% vs 12%, respectively; P = .02). @entity1761 was better tolerated than @entity11884 . CONCLUSIONS: Addition of @entity1761 to @entity11884 therapy significantly reduced the risk and duration of hospitalizations for @entity99 .
